A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer.
Kelly C, Beamish R, McCaffrey J, SMITH M, Crown J, O'Connor M, McGee S, O'Reilly S, Moylan E, Gonzalez-Angulo A, Litton J, Pusztai L, Kelly C. A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer. Journal Of Clinical Oncology 2013, 31: 598-598. DOI: 10.1200/jco.2013.31.15_suppl.598.Peer-Reviewed Original ResearchRisk of recurrenceOncotype DX recurrence scoreRecurrence scoreDX recurrence scoreClinicopathologic factorsBreast cancerRecurrence risk assessmentDistant recurrenceNode negativeIR groupOncotype DXRisk groupsHER-2 negative breast cancerHER2-negative breast cancerEarly-stage breast cancerProportion of patientsOncotype DX testingNegative breast cancerChemotherapy benefitNodal statusPatient chartsTumor sizeClinical trialsAcademic hospitalLR group